Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial Comparing Sequential First-line Sunitinib and Second-line Avelumab vs First-line Avelumab and Second-line Sunitinib for Metastatic Renal Cell Carcinoma: SUAVE Trial. Hoosier Cancer Research Network GU15-223

NCT03035630 is registered in ClinicalTrials.gov with Guru Sonpavde as lead sponsor.

NCT NCT03035630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03035630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial Comparing Sequential First-line Sunitinib and Second-line Avelumab vs First-line Avelumab and Second-line Sunitinib for Metastatic Renal Cell Carcinoma: SUAVE Trial. Hoosier Cancer Research Network GU15-223
Lead sponsor
Guru Sonpavde
Phase
Phase 2
Overall status
Withdrawn
Start date
May 23, 2017
Completion date
December 31, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clear-cell kidney carcinoma, clear-cell renal cell carcinoma, kidney cancer, rcc